IDH2 and acute myeloid leukemia: In primary patient samples NADPH levels were significantly reduced relative to CD34+ controls for IDH1-mutant, but not IDH2-mutant AML (Fig. 4e), consistent with reports from studies with IDH1-mutant solid tumours41,49,52.